Scynexis 2025 Q3 Earnings Net Loss Widens 205.9% Amid $24.8M GSK Settlement

, . The results fell short of expectations, . Analysts maintain a “buy” rating, but price targets have been reduced, reflecting mixed investor sentiment.

Revenue

, driven entirely by a license agreement with GSK. , with no other revenue segments contributing to the decline. The single-source revenue highlights the company’s reliance on partnership-driven income.

Earnings/Net Income

Scynexis’s losses expanded significantly, , . , underscoring the company’s deteriorating profitability. The EPS decline reflects heightened operational costs and a lack of revenue diversification.

Post-Earnings Price Action Review

The strategy of buying SCYX shares on revenue announcements and holding for 30 days yielded mixed results over three years. While the Q3 2025 report led to short-term price appreciation, other quarters, such as Q2 2025, saw declines. , . Analysts retained a “buy” rating, , signaling tempered optimism. Investors must weigh high volatility against potential gains.

CEO Commentary

CEO highlighted two key developments: positive Phase 1 data for SCY-247, a next-generation , and the GSK settlement. He emphasized SCY-247’s favorable tolerability and plans to advance it to Phase 2 trials in 2026. The GSK resolution, he noted, “provides a capital infusion to extend our runway and accelerate innovation.”

Guidance

Scynexis expects to initiate a Phase 1 IV study for SCY-247 in Q1 2026 and a Phase 2 oral study in invasive candidiasis. , pending regulatory transfer.

Additional News

1. GSK Settlement: Resolved a dispute over the MARIO study, , extending cash runway beyond two years.

2. SCY-247 Development: Positive for the oral formulation prompted plans to advance to Phase 2 trials in 2026.

3. BREXAFEMME Relaunch: GSK remains committed to transferring the NDA by year-end, with potential milestones and royalties expected post-relaunch.